Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05821777 |
| Title | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Centessa Pharmaceuticals (UK) Limited |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | FRA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Sarah Cannon Research Institute at HealthONE. | Denver | Colorado | 80218 | United States | Details | |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Sarasota | Florida | 34232 | United States | Details | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
| Sarah Cannon Research Institute at Tennessee Oncology Nashville | Nashville | Tennessee | 37203 | United States | Details | |
| NEXT Oncology - Dallas | Irving | Texas | 75039 | United States | Details | |
| NEXT Oncology | San Antonio | Texas | 78229 | United States | Details | |
| Institut Gustave Roussy | Villejuif | 94805 | France | Details |